Maria Taboada

4.0k total citations · 2 hit papers
16 papers, 855 citations indexed

About

Maria Taboada is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Maria Taboada has authored 16 papers receiving a total of 855 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 3 papers in Surgery. Recurrent topics in Maria Taboada's work include Cancer Immunotherapy and Biomarkers (6 papers), Prostate Cancer Treatment and Research (4 papers) and Bone health and treatments (3 papers). Maria Taboada is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Prostate Cancer Treatment and Research (4 papers) and Bone health and treatments (3 papers). Maria Taboada collaborates with scholars based in United Kingdom, United States and Belgium. Maria Taboada's co-authors include Scott Antonia, Paul K. Stockman, Anne S. Tsao, Joachim G.J.V. Aerts, M. Puglisi, Dariusz M. Kowalski, Alessandra Bearz, Kristiaan Nackaerts, S. Cedrés and Arnaud Scherpereel and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and British Journal of Cancer.

In The Last Decade

Maria Taboada

16 papers receiving 844 citations

Hit Papers

Three-Year Overall Survival with Durvalumab after Chemora... 2017 2026 2020 2023 2019 2017 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
    2019 305 citations Jhanelle E. Gray, Augusto Villegas et al. Journal of Thoracic Oncology profile →
  2. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
    2017 304 citations Michele Maio, Arnaud Scherpereel et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maria Taboada United Kingdom 11 524 510 101 74 64 16 855
Pedro Nazareth Aguiar Brazil 13 428 0.8× 584 1.1× 122 1.2× 70 0.9× 84 1.3× 73 861
Ayako Shiono Japan 15 389 0.7× 605 1.2× 185 1.8× 71 1.0× 44 0.7× 59 783
Atsuto Mouri Japan 16 385 0.7× 520 1.0× 86 0.9× 72 1.0× 42 0.7× 72 677
Anastasios Dimou United States 16 311 0.6× 481 0.9× 56 0.6× 71 1.0× 67 1.0× 67 800
Charles Ricordel France 14 529 1.0× 467 0.9× 36 0.4× 64 0.9× 60 0.9× 74 787
Hayato Kawachi Japan 12 435 0.8× 549 1.1× 88 0.9× 40 0.5× 83 1.3× 35 711
Tsukihisa Yoshida Japan 14 456 0.9× 377 0.7× 24 0.2× 42 0.6× 73 1.1× 34 650
Ou Yamaguchi Japan 19 677 1.3× 910 1.8× 207 2.0× 78 1.1× 67 1.0× 88 1.1k
Rossana Casaretti Italy 15 209 0.4× 526 1.0× 55 0.5× 54 0.7× 105 1.6× 44 657
Lionel Bosquée Belgium 18 514 1.0× 415 0.8× 93 0.9× 88 1.2× 29 0.5× 39 811

Countries citing papers authored by Maria Taboada

Since Specialization
Citations

This map shows the geographic impact of Maria Taboada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Taboada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Taboada more than expected).

Fields of papers citing papers by Maria Taboada

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Taboada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Taboada. The network helps show where Maria Taboada may publish in the future.

Co-authorship network of co-authors of Maria Taboada

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Taboada. A scholar is included among the top collaborators of Maria Taboada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Taboada. Maria Taboada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Gray, Jhanelle E., Augusto Villegas, Davey B. Daniel, et al.. (2019). Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC. Journal of Thoracic Oncology. 15(2). 288–293. 305 indexed citations breakdown →
3.
Gray, Jhanelle E., Augusto Villegas, Davey B. Daniel, et al.. (2019). Three-year overall survival update from the PACIFIC trial.. Journal of Clinical Oncology. 37(15_suppl). 8526–8526. 25 indexed citations
4.
Vansteenkiste, Johan, Jarushka Naidoo, Corinne Faivre‐Finn, et al.. (2019). Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC). Annals of Oncology. 30. v592–v593. 12 indexed citations
5.
Baverel, Paul, Lorin Roskos, Nancy Lee, et al.. (2019). Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status. Clinical and Translational Science. 12(5). 450–458. 16 indexed citations
6.
Wu, Yi‐Long, Jhanelle E. Gray, Augusto Villegas, et al.. (2019). Three-year overall survival update from the PACIFIC trial. Annals of Oncology. 30. ix108–ix109. 1 indexed citations
7.
Maio, Michele, Arnaud Scherpereel, Luana Calabrò, et al.. (2017). Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. The Lancet Oncology. 18(9). 1261–1273. 304 indexed citations breakdown →
8.
Kindler, Hedy L., Arnaud Scherpereel, Luana Calabrò, et al.. (2016). Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study.. Journal of Clinical Oncology. 34(15_suppl). 8502–8502. 31 indexed citations
9.
Taboada, Maria, David Melnick, Joseph P. Iaconis, et al.. (2015). Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy. 71(4). 862–870. 21 indexed citations
10.
Jürgensmeier, Juliane M., Hans‐Joachim Schmoll, Jane Robertson, et al.. (2013). Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. British Journal of Cancer. 108(6). 1316–1323. 50 indexed citations
11.
Trump, Donald L., Heather Payne, Kurt Miller, et al.. (2011). Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration‐resistant prostate cancer. The Prostate. 71(12). 1264–1275. 16 indexed citations
12.
Tomkinson, Helen, John Kemp, Stuart Oliver, et al.. (2011). Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies. PubMed. 11(1). 3–3. 27 indexed citations
13.
14.
15.
16.
Tomkinson, Helen, Eva Engelhardt, S. Oliver, et al.. (2009). 1238 An open-label study of the pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in subjects with mild, moderate, or severe renal impairment, or normal renal function. European Journal of Cancer Supplements. 7(2). 132–132. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pedro Nazareth Aguiar Breakdown of academic impact, for papers by Ayako Shiono Breakdown of academic impact, for papers by Atsuto Mouri Breakdown of academic impact, for papers by Anastasios Dimou Breakdown of academic impact, for papers by Charles Ricordel Breakdown of academic impact, for papers by Hayato Kawachi Breakdown of academic impact, for papers by Tsukihisa Yoshida Breakdown of academic impact, for papers by Ou Yamaguchi Breakdown of academic impact, for papers by Rossana Casaretti Breakdown of academic impact, for papers by Lionel Bosquée
Rankless by CCL
2026